Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients

Yueliang Xie, Xin Jin, Shanshan Yan, Cuifang Wu, Bi-Xiao Xiang, Hui Wang, Liang Wu, Bing-chang Yang, Xuefei Xiao, Zhiling Li, Qi Pei, Xiao‐cong Zuo, Yue PengFrontiers in Pharmacology 2022 · DOI

TL;DR

This study establishes a population pharmacokinetic (PPK) model for intravenous colistin sulfate in critically ill patients, revealing that standard label-recommended doses are frequently insufficient. By identifying renal function (CrCL) and liver health (ALT) as key drivers of drug disposition, the researchers provide a roadmap for personalized dosing to combat multidrug-resistant infections more effectively.

What Problem Does This Paper Address?

As multidrug-resistant (MDR) Gram-negative "superbugs" become more prevalent, clinicians are increasingly turning to polymyxins—a class of "last-resort" antibiotics. While Colistin Methanesulfonate (CMS) is widely used, it is an inactive prodrug that must be converted by the body. In contrast, colistin sulfate is the active form, yet we have surprisingly little data on how it behaves (its pharmacokinetics) in humans, particularly in the chaotic physiological environment of an Intensive Care Unit (ICU).

Critically ill patients often experience extreme variability in how they process drugs due to organ dysfunction. Without a clear understanding of how colistin sulfate is cleared and distributed, doctors risk under-dosing (leading to treatment failure and antibiotic resistance) or over-dosing (leading to toxicity). This paper seeks to close that gap by modeling the drug's behavior and simulating better dosing strategies.

Methods

The researchers conducted a prospective study of 20 critically ill adult patients. They used a combination of high-tech measurement and mathematical modeling:

  • Quantification: Plasma and urine concentrations were measured using ultraperformance liquid chromatography-tandem mass spectrometry (LC-MS/MS), a highly sensitive "gold standard" for drug levels.
  • PPK Modeling: Using the Phoenix NLME program, they developed a non-linear mixed-effects model. They tested one- and two-compartment models to see which best described the drug's movement through the body.
  • Covariate Analysis: They performed a stepwise search to see which patient factors (like age, weight, or lab results) statistically influenced the drug's clearance (CL) and volume of distribution (V).
  • Monte Carlo Simulations: They simulated 1,000 "virtual patients" across 12 different dosing regimens to calculate the Probability of Target Attainment (PTA)—the likelihood that a specific dose would reach the concentration needed to kill bacteria with various levels of resistance (MICs).

Datasets

The study relied on a primary clinical dataset collected at The Third Xiangya Hospital in China between May 2021 and April 2022:

  • Plasma Samples: 98 concentrations from 20 patients.
  • Urine Samples: 41 samples from 6 patients (used specifically to study renal vs. non-renal clearance).
  • Patient Profiles: Detailed demographic and clinical data, including renal function (CrCL) and liver enzymes (ALT).

Key Insights and Ideas

  • The Non-Renal Mystery: One of the most significant findings was that colistin sulfate is predominantly cleared by non-renal pathways. Only about 10% of the drug was recovered in urine. This suggests the liver or other metabolic pathways play a much larger role than previously thought for this specific form of colistin.
  • Kidneys and Liver Matter: The model identified Creatinine Clearance (CrCL) as a major factor for drug clearance and Alanine Aminotransferase (ALT) as a factor for peripheral distribution. This means dosing shouldn't just look at the kidneys; liver health is a piece of the puzzle.
  • Standard Doses are Falling Short: The current "label" recommendation of 1.0–1.5 million units (MU) per day is only effective for very sensitive pathogens (MIC ≤ 0.5 mg/L). For many common ICU infections, this dose is sub-therapeutic.
  • The Necessity of Loading Doses: Simulations showed that a loading dose is essential to reach target therapeutic levels on the first day of treatment, which is critical for treating severe sepsis.

Key Results

  • Model Fit: A two-compartment model with linear elimination best described the data.
  • Clearance Stats: The typical clearance (CL) was 1.50 L/h. Renal clearance (CLR) was only a small fraction (median 12.37% of total clearance).
  • Dosing Recommendations:
    • For patients with normal renal function (CrCL ≥ 80 mL/min), a dose of at least 2.0 MU/day is needed.
  • For patients with renal impairment (CrCL ≤ 10 mL/min), a lower maintenance dose of 1.0 MU/day is appropriate.
  • If the infecting pathogen has an MIC ≥ 1.0 mg/L, standard doses will likely fail, and higher-intensity regimens must be considered.

Limitations and Future Work

The authors acknowledge several limitations:

  1. Small Sample Size: With only 20 patients (and only 6 providing urine), the model would benefit from a larger, multi-center validation.
  2. Protein Binding: The study used a fixed value for the "unbound" (active) fraction of the drug from previous literature. Since ICU patients often have low protein levels, measuring the free drug concentration directly in future studies would be more accurate.
  3. Non-Renal Pathways: While the study proved that non-renal clearance is dominant, it didn't identify exactly where the drug goes (e.g., biliary excretion). Further research into the liver's role in colistin metabolism is needed.

Overall, this paper provides a much-needed pharmacological foundation for using colistin sulfate in the ICU, moving away from "one-size-fits-all" dosing toward a more precise, patient-specific approach.

Summary updated

Abstract

<b>Aims:</b> To explore the population pharmacokinetics of colistin sulfate and to optimize the dosing strategy for critically ill patients. <b>Methods:</b> The study enrolled critically ill adult patients who received colistin sulfate intravenously for more than 72 h with at least one measurement of plasma concentration. Colistin concentrations in plasma or urine samples were measured by ultraperformance liquid chromatography tandem mass spectrometry (LC-MS/MS). The population pharmacokinetics (PPK) model for colistin sulfate was developed using the Phoenix NLME program. Monte Carlo simulation was conducted to evaluate the probability of target attainment (PTA) for optimizing dosing regimens. <b>Results:</b> A total of 98 plasma concentrations from 20 patients were recorded for PPK modeling. The data were adequately described by a two-compartment model with linear elimination. During modeling, creatinine clearance (CrCL) and alanine aminotransferase (ALT) were identified as covariates of the clearance (CL) and volume of peripheral compartment distribution (V2), respectively. In addition, colistin sulfate was predominantly cleared by the nonrenal pathway with a median urinary recovery of 10.05% with large inter-individual variability. Monte Carlo simulations revealed a greater creatinine clearance associated with a higher risk of sub-therapeutic exposure to colistin sulfate. The target PTA (≥90%) of dosage regimens recommended by the label sheet was achievable only in patients infected by pathogens with MIC ≤0.5 mg/L or with renal impairments. <b>Conclusion:</b> Our study showed that the dose of intravenous colistin sulfate was best adjusted by CrCL and ALT. Importantly, the recommended dosing regimen of 1.0-1.5 million units daily was insufficient for patients with normal renal functions (CrCL ≥80 ml/min) or those infected by pathogens with MIC ≥1.0 mg/L. The dosage of colistin sulfate should be adjusted according to renal function and drug exposure.
BibTeX
@inproceedings{xie2022population,
  author = {Yueliang Xie and Xin Jin and Shanshan Yan and Cuifang Wu and Bi-Xiao Xiang and Hui Wang and Liang Wu and Bing-chang Yang and Xuefei Xiao and Zhiling Li and Qi Pei and Xiao‐cong Zuo and Yue Peng},
  title = {{Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.967412},
}
Figure